0
Home
News
Directory
E-newsletter
Magazine
Events
Data
AgReport
Subscribe
Statement of Monsanto Company on further delays and politicization in European Union glyphosate renewal
Jun. 8, 2016
Monsanto Company
United StatesFollow
United StatesIn response to the outcome of EU Standing Committee meeting on glyphosate, Philip Miller, Ph.D., Monsanto’s vice president of global regulatory and governmental affairs, issued the following statement:
The European Union’s risk assessment on glyphosate has been one of the most thorough evaluations of an agricultural product ever conducted. The risk assessment conducted by the rapporteur member state, Germany, and reviewed by the European Food Safety Authority (EFSA) included more than 90,000 pages of data and 353 studies that had not been part of prior EU reviews. The assessment considered the best available science and concluded that glyphosate poses no unreasonable risk to human health or the environment.
In particular, the EFSA evaluation concluded that glyphosate is unlikely to pose a carcinogenic hazard. This carcinogenicity conclusion was affirmed again last week by the German Federal Institute for Occupational Safety and Health (BAuA). In addition, last month, the Joint WHO/FAO Meeting on Pesticide Residues reaffirmed that glyphosate is unlikely to pose a carcinogenic risk to humans from exposure through the diet. No regulatory body in the world considers glyphosate to be a carcinogen.
Monsanto joins with European farmers and other stakeholders in reinforcing the strong safety conclusions on glyphosate by regulatory and scientific bodies in Europe and around the world. Under the EU regulatory framework, glyphosate should be renewed for a full 15 years on the basis of EFSA’s scientific conclusion. Further delays in this process represent a significant deviation from the EU regulatory framework and set a concerning precedent for other active substances. Regulatory decisions should be based on the best available science.
Source: Monsanto news release
More from AgroNews
Change
Hot TopicSubscribe
| Subscribe Email: | * | |
| Name: | ||
| Mobile Number: | ||
Comment
0/1200
NEWSLETTER